Edwards Lifesciences EW Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $6.3B+3.9% | $6.07B+3.1% | $5.88B+3.5% | $5.69B+2.9% | $5.52B+1.5% | ||
| $1.4B+4.6% | $1.33B+4.0% | $1.28B+6.9% | $1.2B+6.1% | $1.13B+1.3% | ||
| $4.91B+3.7% | $4.73B+2.9% | $4.6B+2.6% | $4.48B+2.1% | $4.39B+1.6% | ||
| 77.9%-0.1pp | 78%-0.2pp | 78.2%-0.7pp | 78.9%-0.6pp | 79.5%0.0pp | ||
| $1.09B+0.8% | $1.08B-0.3% | $1.08B+2.6% | $1.06B+0.4% | $1.05B-0.2% | ||
| $2.14B+2.7% | $2.09B+5.6% | $1.97B+5.0% | $1.88B+3.0% | $1.83B+2.1% | ||
| $62.3M-7.3% | $67.2M-11.1% | $75.6M+85.7% | $40.7M+110% | $19.4M+6,367% | ||
| $1.35B+6.5% | $1.26B-11.3% | $1.43B-3.0% | $1.47B+3.1% | $1.42B+3.3% | ||
| 21.4%+0.5pp | 20.8%-3.4pp | 24.2%-1.6pp | 25.8%0.0pp | 25.8%+0.4pp | ||
| —— | —— | —— | —— | $126.73M+5.3% | ||
| $1.3B+2.0% | $1.27B-19.1% | $1.57B-3.3% | $1.63B+1.0% | $1.61B+4.1% | ||
| $224.9M+3.7% | $216.9M-8.0% | $235.8M+7.0% | $220.4M+25.2% | $176.1M+15.8% | ||
| $1.1B+2.1% | $1.07B-21.5% | $1.37B-67.0% | $4.15B-0.8% | $4.18B+0.1% | ||
| 17.4%-0.3pp | 17.7%-5.6pp | 23.2%-49.7pp | 73%-2.8pp | 75.7%-1.0pp | ||
| $20.6M+53.7% | $13.4M-47.9% | $25.7M-99.1% | $2.74B-0.2% | $2.74B-1.2% | ||
| $1.88+2.7% | $1.83-21.1% | $2.32-66.6% | $6.95-0.7% | $7.00+0.4% | ||
| $1.89+2.7% | $1.84-21.0% | $2.33-66.6% | $6.97-0.6% | $7.01+0.4% | ||
| 2.3B-0.3% | 2.3B-0.6% | 2.4B-0.5% | 2.4B-0.7% | 2.4B-0.7% | ||
| 2.3B-0.3% | 2.3B-0.5% | 2.4B-0.5% | 2.4B-0.6% | 2.4B-0.6% | ||
| $1.85+2.2% | $1.81-20.6% | $2.28-4.6% | $2.39-1.2% | $2.42+3.4% | ||
| $1.84+2.2% | $1.80-20.7% | $2.27-4.6% | $2.38-1.7% | $2.42+3.4% | ||
| $0.04+33.3% | $0.03-40.0% | $0.05-98.9% | $4.57-0.2% | $4.58-1.1% | ||
| $351.6M+8.1% | $325.4M+151% | $129.4M+160% | $49.8M+17.5% | $42.4M+5.0% | ||
| $76.1M+957% | $7.2M-80.7% | $37.3M-40.3% | $62.5M-5.0% | $65.8M-4.5% | ||
| $62.3M-7.3% | $67.2M-11.1% | $75.6M+85.7% | $40.7M+110% | $19.4M+6,367% | ||
| —— | $19.1M-35.4% | $29.58M-26.2% | $40.05M-20.7% | $50.53M-17.2% | ||
| —— | —— | —— | —— | —— | ||
| $6.3B+3.9% | $6.07B+3.1% | $5.88B+3.5% | $5.69B+2.9% | $5.52B+1.5% | ||
| $1.51B+6.1% | $1.42B-10.2% | $1.58B-2.4% | $1.62B+2.7% | $1.58B+2.9% | ||
| 23.9%+0.5pp | 23.4%-3.5pp | 26.9%-1.6pp | 28.5%-0.1pp | 28.6%+0.4pp | ||
| $1.35B+6.5% | $1.26B-11.3% | $1.43B-3.0% | $1.47B+3.1% | $1.42B+3.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Edwards Lifesciences's revenue?
- Edwards Lifesciences (EW) generated $6.3B in revenue over the trailing twelve months, up 14.1% year over year.
- Is Edwards Lifesciences profitable?
- Edwards Lifesciences reported $1.1B in net income over the trailing twelve months, a 17.4% net margin.
- What are Edwards Lifesciences's profit margins?
- Gross margin is 77.9% and operating margin is 21.4%, with a 17.4% net margin.
- What is Edwards Lifesciences's earnings per share?
- Edwards Lifesciences's diluted EPS over the trailing twelve months is $1.88.
- Where does Edwards Lifesciences's income statement data come from?
- Every line is extracted from Edwards Lifesciences's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
